Clinical trial · Observational
Intestinal Flora Differences Between Colorectal Cancer Patients and Healthy Individuals
Intestinal Flora Differences Between Colorectal Cancer Patients and Healthy Individuals: A Case-Control Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational case-control study aims to compare the composition of intestinal microbiota between colorectal cancer (CRC) patients and healthy individuals. Fecal samples from 36 CRC patients and 25 healthy controls were analyzed for bacterial abundance. Results indicate significant differences in beneficial, neutral, and harmful bacterial populations between groups, with CRC patients showing reduced beneficial flora (e.g., Lactobacillus) and increased harmful/neutral flora (e.g., Staphylococcus). Further stratification by cancer stage (I-III) revealed progressive dysbiosis with disease progression.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer; Gut Microbiota Dysbiosis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Not applicable (observational study) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- CRC Patients
- description
- Participants: 36 individuals with histopathologically confirmed colorectal cancer. Data Source: Archived fecal samples and medical records from patients diagnosed between January 2022 and October 2023. Inclusion Criteria: Adults (≥18 years). Newly diagnosed CRC without prior chemotherapy/radiotherapy. Availability of fecal samples collected at diagnosis. Exclusion Criteria: Antibiotic/probiotic use within 3 months before sample collection. Concurrent gastrointestinal infections or inflammatory bowel disease. Subgroups: Stratified by clinical stage (I, II, III) based on TNM classification from medical records.
- interventionNames
- Other: Not applicable (observational study)
- label
- Healthy Controls
- description
- Participants: 25 age- and gender-matched individuals without gastrointestinal diseases or cancer history. Data Source: Archived fecal samples and health screening records from routine check-ups during the same period. Inclusion Criteria: Adults (≥18 years). No history of colorectal polyps, cancer, or chronic gastrointestinal disorders. Normal colonoscopy or fecal occult blood test results. Exclusion Criteria: Antibiotic/probiotic use within 3 months before sample collection. Recent acute gastrointestinal symptoms (e.g., diarrhea, constipation).
- interventionNames
- Other: Not applicable (observational study)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Adults (≥18 years) with histopathologically confirmed colorectal cancer (CRC group) * Archived fecal sample available from time of CRC diagnosis (prior to treatment) * Complete clinical records including TNM staging (I-III) for CRC patients * Age- and gender-matched adults without CRC history (control group) * Archived fecal sample available from routine health check-ups (control group) Exclusion Criteria: * Recent antibiotic or probiotic use (within 3 months) * History of inflammatory bowel disease * Incomplete medical records * For controls: history of colorectal cancer, polyps, or chronic gastrointestinal diseases * For controls: abnormal colonoscopy or fecal occult blood test within the past year
References
Publications (0)
Data not yet available